Blog
RSS FeedPosted by Michael Wonder on 12 Apr 2018
ICER releases draft evidence report on CGRP inhibitors for migraine prevention
11 April 2018 - Public comment period now open until 8 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 05 Apr 2018
ICER to assess medication-assisted therapy for treatment of opioid use disorder
5 April 2018 - Report will be subject of November New England CEPAC meeting; open Input now being accepted until 24 ...
Posted by Michael Wonder on 30 Mar 2018
ICER announces new program to make available draft executable economic models during drug assessment review process
30 March 2018 - Pilot program will allow more extensive evaluation of draft economic models used in ICER's reports. ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...
Posted by Michael Wonder on 16 Mar 2018
ICER releases draft evidence report on CFTR modulator therapies for cystic fibrosis
15 March 2018 - Public comment period now open until 12 April; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018. ...
Posted by Michael Wonder on 13 Mar 2018
America’s “NICE”?
12 March 2018 - “The health of a democratic society may be measured by the quality of functions performed by ...
Posted by Michael Wonder on 13 Mar 2018
ICER requests public comment on two draft scoping documents: treatments for high-risk prostate cancer and amyloidosis
12 March 2018 - The ICER has posted two draft scoping documents outlining planned reviews of 1) three anti-androgen therapies ...
Posted by Michael Wonder on 12 Mar 2018
Regeneron and Sanofi announce plans to make Praluent (alirocumab) more accessible and affordable for patients with the greatest health risk and unmet need
10 March 2018 - For payers willing to reduce access barriers for high-risk patients, companies will offer net price within a ...
Posted by Michael Wonder on 11 Mar 2018
Institute for Clinical and Economic Review updates value-based price benchmark for alirocumab, a PCSK9 inhibitor for treatment of high cholesterol
10 March 2018 - Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, ...
Posted by Michael Wonder on 11 Mar 2018
Is ICER NICEr?
21 February 2018 - Similar to NICE in the UK and the PBAC in Australia, the Institute for Clinical and Economic ...
Posted by Michael Wonder on 20 Feb 2018
Does the USA need a national health technology assessor?
19 February 2018 - In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant ...
Posted by Michael Wonder on 16 Feb 2018
ICER to assess treatments for amyloidosis, prostate cancer in upcoming reports
16 February 2018 - Both reports will be subject of September Midwest CEPAC meeting; open Input now being accepted until 7 ...
Posted by Michael Wonder on 29 Jan 2018
Roche haemophilia drug lowers costs despite high price: ICER
27 January 2018 - A costly new Roche Holding AG drug to treat the bleeding disorder haemophilia A could significantly reduce ...
Posted by Michael Wonder on 11 Jan 2018
Institute for Clinical and Economic Review posts draft scoping document on elagolix for endometriosis
11 January 2018 - Document open to public comment until 1 February 2018. ...